finance
Aptose Biosciences Delays Closing of Hanmi Acquisition to June
Aptose Biosciences said regulatory approvals in South Korea are still pending for its planned acquisition by Hanmi Pharmaceutical. The companies now target closing in June and have received an additional loan advance to continue operations.
May 29, 7:30 AM·1m read1 source
koreaherald.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Aptose Biosciences Inc. announced on May 29, 2026 that the closing of its previously announced acquisition by Hanmi Pharmaceutical Co. Ltd. and its subsidiary has been delayed. Certain Korean regulatory approvals required for the transaction remain in progress. The parties stated they do not expect the review to prevent completion and now target closing for June.
Under the arrangement, Hanmi will acquire all common shares of Aptose not already owned by the Hanmi Purchasers. 88 on the Toronto Stock Exchange. The agreement was first disclosed on November 19, 2025.
0 million advance from Hanmi under an amended loan facility originally announced on September 22, 2025. 0 million advance expected in the coming days. These funds support continuation of the TUSCANY clinical trial evaluating tuspetinib in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationLimited · 1 source
